Table 2.
Top pathways enriched with genes influencing treatment response in oral cancer patients not receiving platinum-based chemotherapy.
| Pathway identifier | Pathway name | P value | FDR | Influential genes enriched in pathway |
|---|---|---|---|---|
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression | 3.21E−12 | 1.70E−10 | HIST1H2BM; H2AFJ; H2AFZ; HIST1H2AJ; HIST1H2BK; H3F3A; POLR1C; H2AFV; HIST2H3C; HIST2H2BE |
| R-HSA-5250913 | Positive epigenetic regulation of rRNA expression | 8.82E−11 | 3.00E−09 |
HIST1H2BM; H2AFJ; H2AFZ; HIST1H2AJ;
HIST1H2BK; H3F3A; POLR1C; H2AFV; HIST2H3C; HIST2H2BE |
| R-HSA-1296065 | Inwardly rectifying K+ channels | 2.40E−03 | 9.61E−03 | GNG2; KCNJ14; GNB3 |
| R-HSA-1839130 | Signaling by activated point mutants of FGFR3 | 2.78E−03 | 1.07E−02 | FGFR3 |
| R-HSA-5655332 | Signaling by FGFR3 in disease | 3.91E−03 | 1.17E−02 | KRAS; FGFR3 |
| R-HSA-8853338 | Signaling by FGFR3 point mutants in cancer | 3.91E−03 | 1.17E−02 | KRAS; FGFR3 |
| R-HSA-2033514 | FGFR3 mutant receptor activation | 8.05E−03 | 2.42E−02 | FGFR3 |
| R-HSA-5654227 | Phospholipase C-mediated cascade; FGFR3 | 3.48E−02 | 6.96E−02 | FGFR3 |
| R-HSA-6803211 | TP53 Regulates Transcription of Death Receptors and Ligands | 3.48E−02 | 6.96E−02 | TNFRSF10D |
| R-HSA-2033515 | t(4; 14) translocations of FGFR3 | 4.73E−02 | 9.46E-02 | FGFR3 |
| R-HSA-5619109 | Defective SLC6A2 causes orthostatic intolerance (OI) | 4.73E−02 | 9.46E−02 | SLC6A5 |
| R-HSA-432030 | Transport of glycerol from adipocytes to the liver by Aquaporins | 4.73E−02 | 9.46E−02 | AQP7 |
| R-HSA-1226099 | Signaling by FGFR in disease | 5.37E−02 | 9.73E−02 | KRAS; FGFR3 |
Abbreviations: FDR, false discovery rate.